Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Ioana Agache, Jessica Beltran, Cezmi Akdis, Mubeccel Akdis, Carlos Canelo-Aybar, Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O’Mahony, Nikolaos G. PapadopoulosAlberto Papi, Hae-Sim Park, Luis Pérez de Llano, Margarita Posso, Claudio Rocha, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Yang Song, Corinna Steiner, Jurgen Schwarze, Pablo Alonso-Coello, Oscar Palomares, Marek Jutel

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Originalspråkengelska
TidskriftAllergy : European journal of allergy and clinical immunology
Volym75
Utgåva5
Sidor (från-till)1023-1042
Antal sidor20
ISSN0105-4538
DOI
StatusPublicerad - maj 2020
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3111 Biomedicinska vetenskaper
  • 3121 Inre medicin

Citera det här